BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 30307529)

  • 21. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.
    Scott DW; Chan FC; Hong F; Rogic S; Tan KL; Meissner B; Ben-Neriah S; Boyle M; Kridel R; Telenius A; Woolcock BW; Farinha P; Fisher RI; Rimsza LM; Bartlett NL; Cheson BD; Shepherd LE; Advani RH; Connors JM; Kahl BS; Gordon LI; Horning SJ; Steidl C; Gascoyne RD
    J Clin Oncol; 2013 Feb; 31(6):692-700. PubMed ID: 23182984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
    Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
    Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System.
    Veldman-Jones MH; Lai Z; Wappett M; Harbron CG; Barrett JC; Harrington EA; Thress KS
    Clin Cancer Res; 2015 May; 21(10):2367-78. PubMed ID: 25301847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
    Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
    Front Immunol; 2021; 12():732006. PubMed ID: 34745101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients.
    Lim EL; Trinh DL; Scott DW; Chu A; Krzywinski M; Zhao Y; Robertson AG; Mungall AJ; Schein J; Boyle M; Mottok A; Ennishi D; Johnson NA; Steidl C; Connors JM; Morin RD; Gascoyne RD; Marra MA
    Genome Biol; 2015 Jan; 16(1):18. PubMed ID: 25723320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platform independent protein-based cell-of-origin subtyping of diffuse large B-cell lymphoma in formalin-fixed paraffin-embedded tissue.
    Reinders J; Altenbuchinger M; Limm K; Schwarzfischer P; Scheidt T; Strasser L; Richter J; Szczepanowski M; Huber CG; Klapper W; Spang R; Oefner PJ
    Sci Rep; 2020 May; 10(1):7876. PubMed ID: 32398793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.
    Scott DW; Wright GW; Williams PM; Lih CJ; Walsh W; Jaffe ES; Rosenwald A; Campo E; Chan WC; Connors JM; Smeland EB; Mottok A; Braziel RM; Ott G; Delabie J; Tubbs RR; Cook JR; Weisenburger DD; Greiner TC; Glinsmann-Gibson BJ; Fu K; Staudt LM; Gascoyne RD; Rimsza LM
    Blood; 2014 Feb; 123(8):1214-7. PubMed ID: 24398326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.
    Hu C; Liu C; Tian S; Wang Y; Shen R; Rao H; Li J; Yang X; Chen B; Ye L
    BMC Cancer; 2020 Aug; 20(1):814. PubMed ID: 32854645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
    Abdulla M; Hollander P; Pandzic T; Mansouri L; Ednersson SB; Andersson PO; Hultdin M; Fors M; Erlanson M; Degerman S; Petersen HM; Asmar F; Grønbaek K; Enblad G; Cavelier L; Rosenquist R; Amini RM
    Am J Hematol; 2020 Jan; 95(1):57-67. PubMed ID: 31659781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma.
    Dong H; Wang Q; Zhang G; Li N; Yang M; An Y; Xie L; Li H; Zhang L; Zhu W; Zhao S; Zhang H; Guo X
    Cancer Med; 2020 Mar; 9(5):1790-1797. PubMed ID: 31918459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues.
    Yan WH; Jiang XN; Wang WG; Sun YF; Wo YX; Luo ZZ; Xu QH; Zhou XY; Cao JN; Hong XN; Li XQ
    Front Oncol; 2020; 10():803. PubMed ID: 32582543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
    Rade M; Kreuz M; Borkowetz A; Sommer U; Blumert C; Füssel S; Bertram C; Löffler D; Otto DJ; Wöller LA; Schimmelpfennig C; Köhl U; Gottschling AC; Hönscheid P; Baretton GB; Wirth M; Thomas C; Horn F; Reiche K
    Mol Med; 2024 Feb; 30(1):19. PubMed ID: 38302875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome.
    Tzankov A; Gschwendtner A; Augustin F; Fiegl M; Obermann EC; Dirnhofer S; Went P
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2125-32. PubMed ID: 16609025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
    Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
    Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas.
    Le Guellec S; Lesluyes T; Sarot E; Valle C; Filleron T; Rochaix P; Valentin T; Pérot G; Coindre JM; Chibon F
    Ann Oncol; 2018 Aug; 29(8):1828-1835. PubMed ID: 29860427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of N
    Xie Z; Li M; Hong H; Xu Q; He Z; Peng Z
    Bioengineered; 2021 Dec; 12(1):6115-6133. PubMed ID: 34482808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.